Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
Full Year Results 2024
Watch Riad Mishlawi, CEO
Latest stories
Featured
Strong 2024 performance and a positive outlook for 2025
Press Release, Financial Results 26 February 2025
- Hikma receives FDA approval and launches Mercaptopurine Oral Suspension in the US Press Release, Product 27 February 2025 Hikma receives FDA approval and launches Mercaptopurine Oral Suspension in the US
- Strong 2024 performance and a positive outlook for 2025 Press Release, Financial Results 26 February 2025 Strong 2024 performance and a positive outlook for 2025
- Notice of results Press Release, Financial Results 10 February 2025 Notice of results
- Hikma and M42 sign strategic MOU to advance healthcare innovation in the UAE Press Release, Business Development 30 January 2025 Hikma and M42 sign strategic MOU to advance healthcare innovation in the UAE
